Onyx initiates phase III comparison trial in relapsed multiple myeloma
10:10 EDT 6 Jul 2012 | CentreWatch
Onyx Pharmaceuticals, a San Francisco-based global biopharmaceutical company, has begun enrollment in the ENDEAVOR trial, a phase III trial evaluating Kyprolis (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib..
Original Article: Onyx initiates phase III comparison trial in relapsed multiple myeloma
More From BioPortfolio on "Onyx initiates phase III comparison trial in relapsed multiple myeloma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
